Immunology and Immunotherapy of Head and Neck Cancer

Head and Neck Cancer: Emerging Perspectives

Volumn , Issue , 2003, Pages 569-591

  Shibuya, Terry Y ^a,b   Lum, Lawrence G ^c   Pawlowski, Tomasz ^a,b   Whiteside, Theresa L ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medical Center   (United States)

^c Roger Williams Cancer Center   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 6044231341     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012239990-9/50039-4     Document Type: Chapter

References (304)

1. Al-Sarraf M., LeBlanc M., Shanker Giri P.G., Fu K.K., Cooper J., Vuong T., Forastiere I., Adams G., Sakr W.A., Schuller D.E., Ensley J.F. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J. Clin. Oncol. 1998, 16:1310-1317.
2. Himmelwiet B. The Collected Papers of Paul Ehrlich 1957, Pergamon Press, Philadelphia.
3. Burnet F.M. The concept of immunological surveillance. Progress in Experimental Tumor Research 1970, 1. Karger, Oxford. R.S. Schwartz (Ed.).
4. Penn I. Principle of tumor immunity: Immunocompetence and cancer. Biologic Therapy of Cancer 1992, 103-118. Lippincott, Basel. V.T. DeVita, S. Hellman, S.A. Rosenburg (Eds.).
5. Robison L.L., Stoker V., Frizzera G., Heinitz K., Meadows A.T., Filipovich A. Hodgkin's disease in pediatric patients with naturally occurring immune deficiency. Am. J. Pediatr. Hematol. Oncol. 1987, 189-192.
6. Kersy J.H., Shapiro R.S., Heinitz K.J. Lymphoid malignancy in naturally occurring and post bone marrow transplantation immunodeficiency disease. The Nature, Cellular, and Biochemical Basis and Management of Immunodeficiencies 1987, 289-294. Schattauer Verlag, Philadelphia. R.A. Good, E. Lindenlaub (Eds.).
7. Filipovich A.H., Zerbe D., Spector B.D. Lymphomas in persons with naturally occurring immunodeficiency disorders. Pathogenesis of Leukemias and Lymphomas: Environmental Influences 1984, Raven Press, Stuttgart. I.T. McGrath, G.R. O'Connor, B. Ramot (Eds.).
8. Conant M.A., Volberding P., Fletcher V., Lozada F.I., Silverman S. Squamous cell carcinoma in sexual partner of Kaposi's sarcoma patient. Lancet 1982, 1:286.
9. Lozada F., Silverman S., Conant M. New outbreak of oral tumors, malignancies and infectious diseases strikes young male homosexuals. Calif. Dent. J. 1982, 10:39-42.
10. Munoz A., Gomez-Anson B., Abad L., Gonzalez-Spinola J. Squamous cell carcinoma of the larynx in a 29 year old man with AIDS. AJR Am. J. Roentgenol. 1994, 162:232.
11. Singh B., Sabin S., Rofim O., Shaha A., Har-El G., Lucente F.E. Alterations in head and neck cancer occurring in HIV-infected patients. Acta Oncol. 1999, 38:1047-1050.
12. King G.N., Healy C.M., Glover M.T., Kwan J.T.C., Williams D.M., Leigh I.M., Worthington H.V., Thornhill M.H. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N. Engl. J. Med. 1995, 332:1052-1057.
13. Bradford C.R., Hoffman H.T., Wolf G.T., Carey T.E., Baker S.R., McClatchey E. Squamous cell carcinoma of the head and neck in organ transplant recipients: Possible role of oncogenic virus. Laryngoscope 1990, 100:190-194.
14. Oettgen H.F., Old L.J. The history of cancer immunotherapy. Biologic Therapy of Cancer 1991, 87-119. Lippincott, New York. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
15. Feheisen F. Uber die Zuchtung der Erysipel-Kokken auf kunstlichen Nahrboden und die Ubertragbarkeit auf den Menschen. Dtsch. Med. Wochenschr. 1882, 8:533.
16. Bruns P. Die Heilwirkung des Erysipels auf Geschwulste. Beitr. Klin. Chir. 1888, 3:443.
17. Coley W.B. Treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. 1893, 105:487.
18. Pinsky C.M., Camacho F.J., Kerr D., Geller N.L., Klein F.A., Herr H.A., Oettgen H.F. Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder. Cancer Treat. Rep. 1985, 69:47-53.
19. Lanier L.L., Le A.M., Phillips J.H., Warner N.L., Babcock G.F. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NKI-15) antigens. J. Immunol. 1983, 131:1789-1796.
20. Lotzova E., Herberman R.B. Immunobiology of Natural Killer Cells 1986, CRC Press, Philadelphia.
21. Hercend T., Griffin J.D., Bensussan A., Schmidt R.E., Edson M.A., Brennan A., Murray C., Daley J.F., Schlossman S.F., Ritz J. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J. Clin. Invest. 1985, 75:932-943.
22. Hersey P., Bindon G., Edwards A., Murray E., Phillips G., McCarthy W.H. Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2. Int. J. Cancer 1981, 28:685-703.
23. Lotze M.T., Grimm E.A., Mazumder A., Strausser J.L., Rosenberg S.A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T cell growth factor. Cancer Res. 1981, 41:4420-4425.
24. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2- activated autologous human peripheral blood lymphocytes. J. Exp. Med. 1982, 155:1823-1841.
25. Grimm E.A., Ramsey K.M., Mazumder A., Wilson D.J., Djeu J.Y., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J. Exp. Med. 1983, 157:884-897.
26. Lotzova E., McCredie K.B. Natural killer cells and recombinant interleukin-2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. Cancer Immunol. Immunother. 1978, 4:215.
27. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., Seipp C.A., Simpson C.G., White D.E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose inter-leukin-2 alone. N Engl. J. Med. 1987, 316:889-897.
28. Mazumder A., Eberlein T.J., Grimm E.A., Wilson D.J., Keenan A.M., Aamodt R., Rosenberg S.A. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 1984, 53:896-905.
29. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., Matory Y.L., Skibber J.M., Shiloni E., Vetto J.T., Seipp C.A., Simpson C., Reichert C.M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985, 313:1485-1492.
30. Aebersold P., Hyatt C., Johnson S., Hines K., Korack L., Sanders M., Lotze M.T., Topalian S., Yang J., Rosenberg S.A. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response. J. Natl. Cancer Inst. 1991, 83:932-937.
31. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., White D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 1989, 210:474-485.
32. Thompson J.A., Shulman K.L., Benyunes M.C., Lindgren C.G., Collins C., Lange P.H., Bush W.H., Benz L.A., Fefer A. Prolonged continuous intravenous infusion of interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 1992, 10:960-968.
33. Topalian S.L., Solomon D., Avis F.P., Chang A.E., Freerksen D.L., Linehan W.M., Lotze M.T., Robertson C.N., Seipp C.A., Simon P., Simpson C.G., Rosenberg S.A. Immunotherapy of patients with advanced cancer using tumor-infiltrating lympho-cytes and recombinant interleukin-2: A pilot study. J. Clin. Oncol. 1988, 6:839-853.
34. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A., Simpson C.G., Carter C., Bock S., Schwartzentruber D., Wei J.P., White D.E. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report. N. Engl. J. Med. 1988, 319:1676-1680.
35. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L., Merino M.J., Culver K., Miller A.D., Blaese R.M., Anderson W.F. Gene transfer into humans: Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990, 323:570-578.
36. Goedegebuure P.S., Douville L.M., Li H., Richmond G.C., Schoof D.D., Scavone M., Eberlein T.J. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J. Clin. Oncol. 1995, 13:1939-1949.
37. Yoshizawa H., Chang A.E., Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 1991, 147:729-737.
38. Chang A.E., Shu S. Current status of adoptive immunotherapy of cancer. Crit. Rev. Oncol. Hematol. 1996, 22:213-228.
39. Osband M.E., Lavin P.T., Babayan R.K., Graham S., Lamm D.L., Parker B., Sawczuk I.S., Ross S., Krane R.J. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990, 335:994-998.
40. Lavin P.T., Maar R., Franklin M., Ross S., Martin J., Osband M.E. Autolymphocyte therapy for metastatic renal cell carcinoma: Initial clinical results from 335 patients treated in a multisite clinical practice. Transplant. Proc. 1992, 24:3059-3064.
41. Riddell S.R., Greenberg P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 1990, 128:189-201.
42. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., Delgado J.C., Gribben J.G., Nadler L.M. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 1997, 100:2757-2765.
43. Melief C.J. Prospects of T-cell immunotherapy for cancer by peptide vaccination. Semin. Hematol. 1993, 30:32-33.
44. Schulz M., Aichele P., Schneider R., Hansen T.H., Zinkernagel R.M., Hengartner H. Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide. Eur. J. Immunol. 1991, 21:1181-1185.
45. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
46. Riddell S.R., Greenberg P.D. Cellular adoptive immunotherapy after bone marrow transplantation. Cancer Treat. Res. 1995, 76:337-369.
47. Gedde-Dahl T., Fossum B., Eriksen J.A., Thorsby E., Gaudernack G. T cell clones specific for p21 ras-derived peptide: Characterization of their fine specificity and HLA restriction. Eur. J. Immunol. 1993, 23:754-760.
48. Hoosiers J.G., Inman H.W., van der Burg S.H., Drijfhout J.W., Kenemans P., van de Velde C.J., Brand A., Momburg F., Kast W.M., Melief C.J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 1993, 23:2072-2077.
49. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 1992, 52:6380-6384.
50. + T cells. Proc. Natl. Acad. Sci. USA 1994, 91:3171-3175.
51. + cytotoxic T cells. Cancer Res. 1993, 53:2361-3257.
52. Nijman H.W., Houbiers J.G., van der Burg S.H., Vierboom M.P., Kenemans P., Kast W.M., Melief C.J. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: Relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother. 1993, 14:121-126.
53. Papadopoulos E.B., Ladanyi M., Emanuel D., Mackinnon S., Boulad F., Carabasi M.H., Castro-Malaspina H., Childs B.H., Gillio A.P., Small T.N., Young J.W., Kernan N.A., O'Reilly R.J. Infusions of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 1994, 330:1185-1191.
54. Smith C.A., Ng C.Y.C., Heslop H.E., Holladay M.S., Richardson S., Turner E.V., Loftin S.K., Li C., Brenner M.K. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J. Hematother. 1995, 4:73-79.
55. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., Falo L.D. Peptide-pulsed dendritic cells induced antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 1996, 183:283-287.
56. Steinman R.M., Witmer-Pack M., Inaba K. Dendritic cells: Antigen presentation, accessory function and clinical relevance. Adv. Exp. Med. Biol. 1993, 329:1-9.
57. Young J.W., Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 1996, 183:7-11.
58. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J. Exp. Med. 1994, 179:1109-1118.
59. Romani N., Reider D., Heuer M., Ebner S., Kämpgen E., Eibl B., Niederwiser D., Schuler G. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability. J. Immunol. Methods 1996, 196:137-151.
60. Young J.W., Steinman R.M. The hematopoietic development of dendritic cells: A distinct pathway for myeloid differentiation. Stem Cells 1996, 14:376-387.
61. Bender A., Sapp M., Schuler G., Steinman R.M., Bhardwaj N. Improved method for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 1996, 196:121-135.
62. Wright-Browne V., McClain K.L., Talpaz M., Ordonez N., Estrov Z. Physiology and pathophysiology of dendritic cells. Hum. Pathol. 1997, 28:563-579.
63. Knight S.C., Stagg A.J. Antigen-presenting cell types. Curr. Opin. Immunol. 1993, 5:374-382.
64. Inaba K., Metlay J.P., Crowley M.T., Steinman R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigenspecific, MHC-restricted T cells in situ. J. Exp. Med. 1990, 172:631-640.
65. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 1997, 9:10-16.
66. + T lymphocytes respond to denditic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997, 90:290-297.
67. Tjoa B., Erickson S., Barren R., Ragde H., Kenny G., Boynton A., Murphy G. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995, 27:63-69.
68. Tjoa B., Boynton A., Kenny G., Ragde H., Misrock S.L., Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996, 28:65-69.
69. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 1998, 4:321-327.
70. Nair S.K., Snyder D., Rouse B.T., Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer 1997, 70:706-715.
71. Boczkowski D., Nair S.K., Snyder D., Gilboa E. Dendritic cells pulsed with RNA and potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996, 184:465-472.
72. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
73. Kolb H.J., Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol. 1997, 9:139-145.
74. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A. Graftversus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party on Chronic Leukemia. Blood 1995, 86:2041-2050.
75. Levine J.E., Yanik G., Hutchinson R.J., Casper J., Beatty P.G., Sproles A., Collins R. Donor leukocyte infusions (DLI) to treat relapses after allogeneic bone marrow transplantation in pediatric patients. Blood 1997, 90:548a.
76. Collins R.H., Shpilberg O., Drobyski W.R., Porter D.L., Giralt S., Champlin R., Goodman S.A., Wolff S.N., Hu W., Verfaillie C., List A., Dalton W., Ognoskie N., Chetrit A., Antin J.H., Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 1997, 15:433-444.
77. Meuer S.C., Hussey R.E., Cantrell D.A., Hodgdon J.C., Schlossman S.F., Smith K.A., Reinherz E.L. Triggering of the T3-Ti anti-receptor complex results in clonal T cell proliferation through an interleukin 2 dependent autocrine pathway. Proc. Natl. Acad. Sci. USA 1984, 81:1509-1513.
78. Meuer S.C., Hodgdon J.C., Hussey R.E., Protentis J.P., Schlossman S.F., Reinherz E.L. Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones. J. Exp. Med. 1983, 158:988-993.
79. Weiss A., Imboden J.B. Cell surface molecules and early events involved in human T lymphocyte activation. Adv. Immunol. 1987, 41:1-38.
80. Van Wauwe J.P., De Mey J.R., Gooseens J.G. OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immunol. 1980, 124:2708-2713.
81. Loeffler C.M., Platt J.L., Anderson P.M., Katsanis E., Ochoa J.B., Urba W.J., Longo D.L., Leonard A.S., Ochoa A.C. Antitumor effects of IL-2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. Cancer Res. 1991, 51:2127-2132.
82. Murphy W.J., Conlon K.C., Sayers T.J., Wiltrout R.H., Back T.C., Ortaldo J.R., Longo D.L. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J. Immunol. 1993, 150:3634-3642.
83. Katsanis E., Xu Z., Anderson P.M., Dancisak B.B., Bausero M.A., Weisdorf D.J., Blazar B.R., Ochoa A.C. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in vivo expansion of effector cells with potent anti-lymphoma activity. Bone Marrow Transplant 1994, 14:563-572.
84. Chen B.P., Malkovsky M., Hank J.A., Sondel P.M. Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 Moab. Cell. Immunol. 1987, 110:282-293.
85. Lotzova E., Savary C.A., Herberman R.B., McCredie K.B., Keating M.J., Freireich E.J. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: Synergism of OKT3 and interleukin-2. Nature Immun. Cell Growth Regul. 1987, 6:219-223.
86. Yang S.C., Fry K.D., Grimm E.A., Roth J.A. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha. Arch. Surg. 1990, 125:220-225.
87. Anderson P.M., Bach F.H., Ochoa A.C. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol. Immunother. 1988, 27:82-88.
88. Ochoa A.C., Hasz D.E., Rezonzew R., Anderson P.M., Bach F.H. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: Identification and isolation of effector subsets. Cancer Res. 1989, 49:963-968.
89. Anderson P.M., Blazar B.R., Bach F.H., Ochoa A.C. Anti-CD3+ IL-2-stimulated murine killer cells: In vitro generation and in vivo antitumor activity. J. Immunol. 1989, 142:1383-1394.
90. Ting C.-C., Hargrove M.E., Yun Y.S. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. J. Immunol. 1988, 141:741-748.
91. Uberti J.P., Joshi I., Ueda M., Martilotti F., Sensenbrenner L.L., Lum L.G. Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: Optimal conditions for the proliferation and induction of non-MHC restricted cytotoxicity. Clin. Immunol. Immunopathol. 1994, 70:234-240.
92. Ueda M., Joshi I.D., Dan M., Uberti J.P., Chou T.-H., Sensenbrenner L.L., Lum L.G. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. II. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 1993, 56:351-356.
93. Anderson P.M., Ochoa A.C., Ramsay N.K.C., Hasz D., Weisdorf D. Anti-CD3+ interleukin-2 stimulation of marrow and blood: Comparison of proliferation and cytotoxicity. Blood 1992, 80:1846-8153.
94. Ochoa A.C., Gromo G., Alter B.J., Sondel P.M., Bach F.H. Long-term growth of lymphokine-activated killer (LAK) cell: Role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J. Immunol. 1987, 138:2728-2733.
95. Sosman J.A., Oettel K.R., Hank J.A., Sondel P.M. Isolation and characterization of human cytolytic cells (CTL) with specificity for allogeneic leukemic blasts. FASEB J. 1989, 3:506a.
96. Sosman J.A., Oettel K.R., Hank J.A., Fisch P., Sondel P.M. Specific recognition of human leukemic cells by allogeneic T cell lines. Transplantation 1989, 48:486.
97. Massaia M., Attisano C., Peola S., Montacchini L., Omede P., Corradini P., Ferrero D., Boccadoro M., Bianchi A., Pileri A. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 1993, 82:1787-1797.
98. Curti B.C., Longo D.L., Ochoa A.C., Conlon K.C., Smith J.W., Alvord W.G., Creekmore S.P., Fenton R.G., Gause B.L., Holmlund J., Janik J.E., Ochoa J., Rice P.A., Sharfman W.H., Sznol M., Urba W.J. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J. Clin. Oncol. 1993, 11:652-660.
99. + T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J. Clin. Oncol. 1998, 16:2752-2760.
100. Lum L.G., Treisman J.S., Taylor R.F., LeFever A.V. Phase I/II trial of activated T cells (ATC), IL-2, and GM-CSF after PBSC transplant for stage IIIb or IV breast cancer. Blood 1997, 90:381a.
101. Lum L.G. Immunotherapy with activated T cells after high dose chemotherapy and PBSCT for breast cancer. Proc. of the 10th Int'l Symposium on Autologous Blood and Marrow Transplantation 2000, 35-36.
102. June C.H., Ledbetter J.A., Linsley P.S., Thompson C.B. Role of the CD28 receptor in T-cell activation. Immunol. Today 1990, 11:211-216.
103. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol. Today 1994, 15:321-331.
104. Jenkins M.K., Johnson J.G. Molecules involved in T-cell costimulation. Curr. Opin. Immunol. 1993, 5:361-367.
105. Schwartz R.H. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992, 71:1065-1068.
106. Costello R., Cerdan C., Pavon C., Brailly H., Hurpin C., Mawas C., Olive D. The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells. Eur. J. Immunol. 1993, 23:608-613.
107. Thompson C.B., Lindsten T., Ledbetter J.A., Kunkel S.L., Young H.A., Emerson S.G., Leiden J.M., June C.H. CD activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 1989, 86:1333-1337.
108. + T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
109. Garlie N.K., LeFever A.V., Siebenlist R.E., Levine B.L., June C.H., Lum L.G. T cells co-activated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J. Immunother 1999, 4:335-345.
110. + T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol. 1995, 7:891-904.
111. Boise L.H., Noel P.J., Thompson C.B. CD28 and apoptosis. Curr. Opin. Immunol. 1995, 7:620-625.
112. 1. Immunity 1995, 3:87-98.
113. Shibuya T.Y., Wei W.Z., Zormeier M., Ensley J., Sakr W., Mathog R.H., Meleca R.J., Yoo G., June C.H., Levine B., Lum L.G. Anti-CD3/anti-CD28 bead overcomes suppressed T cell responses in HNSCC patients. Arch. Otolaryngol. Head Neck Surg. 2000, 126:473-479.
114. 1 responses in vivo. Exp. Hematol. 1998, 26:772a.
115. Renner C., Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev. 1995, 145:179-209.
116. Bonino L.D., De Monte L.B., Sapnoli G.C., Vola R., Mariani M., Barone D., Moro A.M., Riva P., Niotra M.R., Natali P.G., Malavasi F. Bispecific monoclonal antibody anti-CD3 x antitenascin: An immunotherapeutic agent for human glioma. Int. J. Cancer 1995, 61:509-515.
117. Kaneko T., Fusauchi Y., Kakui Y., Masuda M., Akahoshi M., Termura M., Motoji T., Okumura K., Mizoguchi H., Oshimi K. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 1993, 81:1333-1341.
118. Katayose Y., Kudo T., Suzuki M., Shinoda M., Saijyo S., Sakurai N., Saeki H., Fukuhara K., Imai K., Matsuno S. MUC1-specific targeting immunotherapy with bispecific antibodies: Inhibition of xenografted human bile duct carcinoma growth. Cancer Res. 1996, 56:4205-4212.
119. Mack M., Gruber R., Schmidt S., Riethmüller G., Kufer P. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: Tumor cell-dependent T cell stimulation and cytotoxic activity. J. Immunol. 1997, 158:3965-3970.
120. Bolhuis R.L.H., Lamers C.H.J., Goey S.H., Eggermont A.M.M., Trimbos J.B.M.Z., Stoter G., Lanzavecchia A., di Re E., Mioth S., Raspagliesi F., Rivoltini L., Colnaghi M.I. Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study. Int. J. Cancer 1992, 78-81.
121. Canevari S., Mezzanzanica D., Mazzoni A., Negri D.R.M., Ramakrishna V., Bohuis R.L.H., Colnaghi M.I., Bolis G. Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions. J. Hematother. 1995, 4:423-427.
122. Canevari S., Stoter G., Arienti F., Bolis G., Colnaghi M.I., Di Re E.M., Eggermont A.M.M., Goey S.H., Gratama J.W., Lamers C.H.J., Nooy M.A., Parmiani G., Raspagliesi F., Ravagnani F., Scarfone G., Trimbos J.B., Warnaar S.O., Bolhuis R.L.H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 1995, 87:1463-1469.
123. Lamers C.H.J., van de Griend R.J., Braakman E., Ronteltap C.P.M., Bénard J., Stoter G. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int. J. Cancer 1992, 51:973-979.
124. Zhu Z., Ghose T., Lee S.H., Fernandez L.A., Kerr L.A., Donohue J.H., McKean D.J. Tumor localization and therapeutic potential of an antitumor-CD3-heteroconjugate antibody in human renal cell carcinoma xenograft models. Cancer Lett. 1994, 86:127-134.
125. Van Dijk J., Warnaar S.O., van Eendenburg J.D., Thienpont M., Braakman E., Boot J.H., Fleuren G.J., Bolhuis R.L. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int. J. Cancer 1989, 43:344-349.
126. Tahara H., Lotze M.T. Antitumor effects of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer. Gene Ther. 1995, 2:96-106.
127. Kroesen B.J., ter Haar A., Willemse P., Sleijfer D.T., de Vries E.G.E., Mulder N.H., Berendsen H.H., Limburg P.C., The H.T., de Leij L. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother. 1993, 37:401-407.
128. Anderson P.M., Crist W., Hasz D., Carroll A.J., Myers D.E., Uckun F.M. G19.4(aCD3) x B43(aCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 1992, 80:2826-2834.
129. Bohlen H., Hopff T., Manzke O., Engert A., Kube D., Wickramanayake P.D., Diehl V., Tesch H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993, 82:1803-1812.
130. Bohlen H., Manzke O., Patel B., Moldenhauer G., Dörken B., von Fliedner V., Diehl V., Tesch H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res. 1993, 43:4310-4314.
131. Bejeck B.E., Wang D., Berven E., Pennell C.A., Peiper S.C., Poppema S., Uckun F.M., Kersey J.H. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res. 1995, 55:2346-2351.
132. de Gast G.C., Haagen I.-A., van Houten A.A., Klein S.C., Duits A.J., de Weger R.A., Vroom T.M., Clark M.R., Phillips J., van Dijk A.J.G., de Lau W.B.M., Bast B.J.E.G. CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. 1995, 40:390-396.
133. Klein S.C., Boer L.H., de Weger R.A., de Gast G.C., Bast E.J.E.G. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 × CD19. Scand. J. Immunol. 1997, 46:452-458.
134. Kuwahara M., Kuroki M., Arakawa F., Senba T., Matsuoka Y., Hideshima T., Yamashita Y., Kanda H. A mouse/humanchimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res. 1997, 16:2661-2668.
135. Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trümper L., Hartmann F., Diehl V., van Lier R., Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994, 264:833-835.
136. Renner C., Bauer S., Sahin U., Jung W., van Lier R., Jacobs G., Held G., Pfreundschuh M. Cure of disseminated xenografted human Hodgkin's tumors by bispecifc monoclonal antibodies and human T cells: The role of human T-cell subsets in a preclinical model. Blood 1996, 87:2930-2937.
137. Pohl C., Denfeld R., Renner C., Jung W., Bohlen H., Sahin U., Hombach A., van Lier R., Schwonzen M., Diehl V., Pfreundschuh M. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of Hodgkin's lymphoma. Int. J. Cancer 1993, 54:820-827.
138. Sen M., Wankowski D.M., Garlie N.K., Siebenlist R.E., Van Epps D., LeFever A.V., Lum L.G. Use of anit-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu Tumors. J. Hematother. Stem Cell Res. 2001, 166:299-303.
139. Titus J.A., Perez P., Kaubisch A., Garrido M.A., Segal D.M. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J. Immunol. 1987, 139:3153-3158.
140. Weiner L.M., Clark J.I., Davey M., Li W.S., de Palazzo I.G., Ring D.B., Alpaugh R.K. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 1995, 55:4586-4593.
141. Valone F.H., Kaufman P.A., Guyre P.M., Lewis L.D., Memoli V., Deo Y., Graziano R., Fisher J.L., Meyer L., Mrozek-Orlowski M. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that over expresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 1995, 13:2281-2292.
142. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 1993, 90:720-724.
143. Hwu P., Shafer G.E., Treisman J.S., Schindler D.G., Gross G., Cowherd R., Rosenberg S.A., Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 1993, 178:361-366.
144. Hwu P., Yang J.C., Cowherd R., Treisman J.S., Shafer G.E., Eshhar Z., Rosenberg S.A. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995, 55:3369-3373.
145. Eshhar Z., Bach N., Fitzer-Attas C.J., Gross G., Lustgarten J., Waks T., Schindler D.G. The T-body approach: Potential for cancer immunotherapy. Springer Semin. Immunopathol. 1996, 18:199-209.
146. Altenschmidt U., Moritz D., Groner B. Specific cytotoxic T lymphocytes in gene therapy. J. Mol. Med. 1997, 75:259-266.
147. Fitzer-Attas C.J., Eshhar Z. Tyrosine kinase chimeras for antigen-selective T-body therapy. Adv. Drug Delivery Rev. 1998, 31:171-182.
148. Plavec I., Agarwal M., Ho K.E., Pineda M., Auten J., Baker J., Matsuzaki H., Escaich S., Bonyhadi M., Bohnlein E. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implication for gene therapy. Gene Ther. 1997, 4:128-139.
149. Quinn E.R., Lum L.G., Trevor K.T. T cell activation modulates retrovirus-mediated gene expression. Hum. Gene Ther. 1998, 9:1457-1467.
150. Myers J.N., Whiteside T.L. Immunotherapy of squamous cell carcinoma of the head and neck. Cancer of the Head and Neck 1995, 805-817. Saunders, Boca Raton, FL. 3rd Ed. E. Myers, J. Suen (Eds.).
151. Cortesina G., Sacchi M., Galeazzi E., De Stedfani A. Immunology of head and neck cancer: Perspectives. Head Neck 1993, 15:74-77.
152. Mickel R.A., Kessler D.J., Taylor J.M., Lichtenstein A. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res. 1988, 48:5017-5022.
153. Cortesina G., Sartoris A., DiFortunato V., Cavallo G.P., Morra B., Bussi M., Beatrice F., Poggio E., Marcato P., Rendine S. Natural killer-mediated cytotoxicity in patients with laryngeal carcinoma. Ann. Otol. Rhinol. Laryngol. 1984, 93:189-191.
154. Wang M.B., Lichtenstein A., Mickel R.A. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. 1991, 105:517-527.
155. Letessier E.M., Sacchi M., Johnson J.T., Heberman R.B., Whiteside T.L. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell. Immunol. 1990, 130:446-458.
156. Kessler D.J., Mickel R.A., Lichtenstein A. Depressed natural killer cell activity in cervical lymph nodes containing focal metastatic squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1988, 114:313-318.
157. Heo D.S., Whiteside T.L., Johnson J.T., Chen K.N., Barnes E.L., Heberman R.B. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes (TIL) from human squamous cell carcinomas of the head and neck. Cancer Res. 1987, 47:6353-6362.
158. Horiuchi K., Mishima K., Ohsawa M., Sugimura M., Aozasa K. Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. J. Surg. Oncol. 1993, 53:92-96.
159. Tatake R.J., Krishnan N., Rao R.S., Fakih A.R., Gangal S.G. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer. Int. J. Cancer 1989, 43:560-566.
160. Murali P.S., Somasundaram R., Rao R.S., Fakih A.R., Gangal S.G. Interleukin-2 mediated regulation of mitogenactivated T cell reactivity from different lymphoid sources in patients with squamous cell carcinoma of the oral cavity. J. Oral. Pathol. Med. 1989, 18:327-332.
161. Leess F.R., Bredenkamp J.K., Lichtenstein A., Mickel R.A. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck carcinomas. Laryngoscope 1989, 99:1255-1261.
162. Ortega I.S., Nieto C.S., Forelady M.F.F. Lymph node response and its relationship to prognosis in carcinomas of the head and neck. Clin. Otolaryngol. 1987, 12:241-247.
163. Yasumura S., Weidmann E., Hirabayashi H., Johnson J.T., Herberman R.B., Whiteside T.L. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. Int. J. Cancer 1994, 57:297-305.
164. Vitolo D., Letessier E.M., Johnson J.T., Whiteside T.L. Immunologic effector cells in head and neck cancer. Monogr. Natl. Cancer Inst. 1992, 12:203-208.
165. Vitolo D., Kanbour A., Johnson J.T., Herberman R.B., Whiteside T.L. In situ hybridization for cytokine gene transcripts in the solid tumor microenvironment. Eur. J. Cancer 1993, 29:371-377.
166. Tsukuda M., Mochimatsu I., Sakumoto M., Furukawa S., Yayama S., Yanana S., Kubota A. Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas. Biotherapy 1993, 6:155-161.
167. Yasamura S., Hirabayashi H., Schwartz D.R., Toso J.F., Johnson J.T., Herberman R.B., Whiteside T.L. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res. 1993, 53:1461-1468.
168. + cells in cancers that secrete granulocytemacrophage colony-stimulating factor. Clin. Cancer Res. 1995, 1:956-1103.
169. + cells within head and neck squamous cell carcinoma. J. Immunol. 1997, 159:990-996.
170. Young M.R.I., Wright M.A., Lozano Y., Matthews J.P., Benefield J., Prechel M.M. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer. Int. J. Cancer 1996, 67:333-338.
171. Hiratsuka H., Imamura M., Ishii Y., Kohama G., Kikuchi K. Immunohistologic detection of lymphocyte subpopulations infiltrating in human oral cancer with special reference to its clinical significance. Cancer 1984, 53:2456-2466.
172. Zeromski J., Szmeja A., Rewer A., Kruk-Zagajewska A. Immunofluorescent assessment of tumor-infiltrating cells in laryngeal carcinoma. Acta Otolaryngol. (Stockh.) 1986, 102:325-332.
173. Wolf G.T., Hudson J.L., Peterson K.A., Miller H.L., McClatchey K.D. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: Correlations with extent of tumor and prognosis. Otolaryngol. Head Neck Surg. 1986, 95:142-152.
174. Bennest S.H., Futrell J.W., Roth J.A., Hoye R.C., Ketcham A.S. Prognostic significance of histological host response in cancer of the larynx or hypopharynx. Cancer 1971, 28:1255-1265.
175. Hirota J., Vetq E., Osaki T., Ogawa Y. Immunohistologic study of mononuclear cell infiltrates in oral squamous cell carcinomas. Head Neck 1990, 12:118-125.
176. Snyderman C.H., Heo D.S., Chen K., Whiteside T.L., Johnson J.T. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer. Head Neck 1990, 12:118-125.
177. Whiteside T.L., Heo D.S., Chen K. Expansion of tumor-infiltrating lymphocytes from human solid tumors in interleukin-2. Progress in Clinical and Biological Research 1987, 213-222. A.R. Liss, Philadelphia. R.L. Truitt, R.P. Gale, M.M. Bortin (Eds.).
178. Snyderman C.H., Heo D.S., Johnson J.T., D'Amico F., Barnes L., Whiteside T.L. Functional and phenotypic analysis of lymphocytes isolated from tumors and lymph nodes of patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 1991, 117:899-905.
179. Nomori H., Watanabe S., Nakajima T., Shimosato Y., Kameya T. Histiocytes in naso-pharyngeal carcinoma in relations to prognosis. Cancer 1986, 57:100-105.
180. Neuchrist C., Grasl M., Scheiner O., Lassmann H., Ehrenberger K., Kraft D. Squamous cell carcinoma: Infiltrating monocyte/macrohage subpopulations express functional mature phenotype. Br. J. Cancer 1990, 62:748-753.
181. Horst H.-A., Horny H.-P. Tumor-infiltrating lymphoreticular cells. Histologic and immunohistologic investigations performed on metastasizing squamous cell carcinomas of the head and neck. Cancer 1991, 68:2397-2402.
182. Cozzolino F., Torcia M., Carossino A.M., Giordani R., Selli C., Talini G., Reali E., Novelli A., Pistoia V., Ferrarini M. Characterization of cells from invaded lymph nodes in patients with solid tumors: Lymphokine requirement for tumor-specific lymphoid proliferative response. J. Exp. Med. 1987, 166:303-318.
183. Wustrow T.P.U., Kabelitz D. Interleukin-2 release from lymphocytes of patients with head and neck cancer. Ann. Otol. Rhinol. Laryngol. 1987, 98:179-184.
184. Vinzenz K., Micksche M. Natural cytotoxicity in draining lymph nodes of squamous cell cancer in the maxillofacial region. J. Oral. Maxillofac. Surg. 1987, 45:42-47.
185. Eura M., Maehara T., Ikawa T., Ishikawa T. Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients. Cancer Immunol. Immunother. 1988, 27:147-153.
186. + T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer. Cancer Res. 1991, 51:3891-3899.
187. Roubin R., Bekkoucha F., Fondaneche M.-C., Quan P.C., Micheau C., Cachin Y., Burtin P. Lymphoid cells in lymph nodes and peripheral blood of patients with squamous cell carcinoma of the head and neck. J. Cancer Res. Clin. Oncol. 1982, 102:277-287.
188. Schuller D.E., Rock R.P., Rinehart J.J., Koolemans-Beynen A.R. T-lymphocytes as a prognostic indicator in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 1986, 112:938-941.
189. Eskinazi D.P., Helman J., Ershow A.G., Perna J.J., Mihail R. Nonspecific immunity and head and neck cancer: Blastogenesis reviewed and revisited. Oral. Surg. Oral. Med. Oral. Pathol. 1985, 60:642-647.
190. Eilber F.R., Morton D.L., Ketcham A.S. Immunologic abnormalities in head and neck cancer. Am. J. Surg. 1974, 128:534-538.
191. Wanebo H.J., Jun M.Y., Strong E.W., Oettgen H. T-cell deficiency in patients with squamous cell cancer of the head and neck. Am. J. Surg. 1975, 130:445-451.
192. Mason J.M., Kitchens G.G., Eastham R.J., Jennings B.R. T-lymphocytes and survival of head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1977, 103:233-236.
193. Ryan R.E., Neel H.B., Ritts R.E. Correlation of preoperative immunologic test results with recurrence in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 1980, 88:58-63.
194. Papenhausen P.R., Kukwa A., Croft C.B., Borowiencki B., Silver C., Emeson E.E. Cellular immunity in patients with epidermoid cancer of the head and neck. Laryngoscope 1979, 89:538-549.
195. Eskinazi D.P., Perna J.J., Ershow A.G., Mihail R.C. Depressed PMNC blastogenic response in patients with cancer of the head and neck: A study of IL-2 production, IL-2 consumption, and IL-2 receptor expression. Laryngoscope 1989, 99:151-157.
196. Wanebo H.J., Jones T., Pace R., Cantrell R., Levine P. Immune restoration with interleukin-2 in patient with squamous cell carcinomas of the head and neck. Am. J. Surg. 1989, 158:356-360.
197. Hargett S., Wanebo H.J., Pace R., Katz D., Sando J., Cantrell R. Interleukin-2 production in head and neck cancer patients. Am. J. Surg. 1985, 150:456-460.
198. 1 in vitro. Arch. Otolaryngol. Head Neck Surg. 1989, 115:1345-1349.
199. Wolf G.T., Lovett E.J., Peterson K.A., Beauchamp M.L., Baker S.R. Lymphokine production and lymphocyte subpopulations in patients with head and neck squamous carcinoma. Arch. Otolaryngol. Head Neck Surg. 1984, 110:731-735.
200. M) in oral cancer. Cancer 1983, 52:1837-1840.
201. Johnson J.T., Rabin B.S., Hirsch B., Thearle P.B. T-cell subpopulations in head and neck carcinoma. Arch. Otolaryngol. Head Neck Surg. 1984, 92:381-385.
202. Dawson D.E., Everts E.C., Vetto R.M., Burger D.R. Assessment of immunocompetent cells in patients with head and neck squamous cell carcinoma. Ann. Otol. Rhinol. Laryngol. 1985, 94:342-345.
203. Strome M., Clark J.R., Fried M.P., Rodliff S., Blazar B.A. T-cell subsets and natural killer cell function with squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 1987, 113:1090-1093.
204. Wolf G.T., Schmaltz S., Hudson J., Robson H., Stackhouse T., Peterson K.A., Poore J.A., McClatchey K.D. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 1987, 113:1200-1206.
205. Schantz S.P., Liu F.J. An immunologic profiles of young adults with head and neck cancer. Cancer 1989, 64:1232-1237.
206. Berlinger N.T., Tsakraklides V., Pollak K., Adams G.L., Yang M., Good R.A. Immunologic assessment of regional lymph node histology in relation to survival in head and neck carcinoma. Cancer 1976, 37:697-705.
207. Berlinger N.T., Tsakraklides V., Pollak K., Adams G.L., Yang M., Good R.A. Prognostic significance of lymph node histology in patients with squamous cell carcinoma of the larynx, pharynx, or oral cavity. Laryngoscope 1976, 86:792-803.
208. Ring A.H., Sako K., Rao U., Razack M.S., Reese P. Immunologic patterns of regional lymph nodes in squamous cell carcinoma of the floor of the mouth: Prognostic significance. Am. J. Surg. 1985, 150:461-465.
209. Kuss I., Saito T., Johnson J.T., Whiteside T.L. Clinical significance of decreased ξ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin. Cancer Res. 1999, 5:329-334.
210. Brookes G.B., Clifford P. Nutritional status and general immune competence in patients with head and neck cancer. JR Soc. Med. 1981, 74:132-139.
211. Good R.A., Fernandez G., West A. Nutrition, immunity and cancer: A review. I. Influence of protein or protein-calorie malnutrition and zinc deficiency on immunity. Clin. Bull. 1979, 9:3-12.
212. Hadden J.W. Immunology of head and neck cancer. Clin. Immunother. 1995, 3:362-385.
213. Coto J.A., Hadden E.M., Sauro M., Zorn N., Hadden J.W. Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear kinase C. Proc. Natl. Acad. Sci. USA 1992, 89:7752-7756.
214. Abdulla M., Biorklund A., Mathur A., Walleniusk K. Zinc and copper levels in whole blood and plasma from patients with squamous cell carcinoma of head and neck. J. Surg. Oncol. 1979, 12:107-113.
215. Johnson J.T., Rabin B.S., Wagner R.L. Prostaglandin E2 of the upper aerodigestive tract. Ann. Otolaryngol. Rhinol. Laryngol. 1987, 96:213-216.
216. Snyderman C.H., Kaplan I., Milanovich M., Heo D.S., Wagner R., Schwartz M., Johnson J.T., Whiteside T.L. Comparison of in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. Otolaryngol. Head Neck Surg. 1994, 111:189-196.
217. Goodwin J.S., Ceuppens J. Regulation of the immune response by prostaglandins. J. Clin. Immunol. 1983, 3:295-315.
218. Panje W.R. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch. Otolaryngol. 1981, 107:658-663.
219. Hirsch B., Johnson J.T., Rabin B.S., Thearle P.B. Immunostimulation of patients with head and neck cancer. Arch. Otolaryngol. 1983, 109:298-301.
220. Cross D.S., Platt J.L., Juhn S.K., Bach F.H., Adams G.L. Administration of a prostaglandin synthesis inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 1992, 118:526-528.
221. Simons P.J., Oostendorp R.A., Tas M.P., Drexhage H.A. Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer. Cancer Immunol. Immunother. 1994, 38:178-184.
222. Tan I.B., Drexhage H.A., Mullink R., Hensen-Logmans S., Snow G.B., Balm A.J. Immunohistochemical detection of retro viral - P15E-related material in carcinoma of the head and neck. Otolaryngol. Head Neck Surg. 1987, 96:251-255.
223. Nelson M., Nelson D.S., Spradbrow P.B., Kuchroo V.K., Jennings P.A., Synderman R. Successful tumor immunotherapy: Possible role of antibodies to anti-inflammatory factors produced by neoplasms. Clin. Exp. Immunol. 1985, 61:109-117.
224. Mann E.A., Spiro J.D., Chen L.L., Kreutzer D.L. Cytokine expression by head and neck squamous cell carcinoma. Am. J. Surg. 1992, 164:567-573.
225. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J.C., Tschopp J. Melanoma cell expression of Fas ligand: Implications for tumor immune escape. Science 1996, 274:1363-1366.
226. Bennett M.W., O'Connell J. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 1998, 160:5669-5675.
227. Gratas C., Tohma Y., Barnas C., Taniere P., Hainaut P., Ohgaki H. Upregulation of Fas ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998, 58:2057-2062.
228. Walker P.R., Saas P., Dietrich P.Y. Role of fas ligand (CD95L) in immune escape: The tumor cell strikes back. J. Immunol. 1997, 158:4521-4524.
229. Cardi G., Heaney J.A., Schned A.R., Ernstoff M.S. Expression of Fas in tumor infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 1998, 58:2078-2080.
230. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahas F. Fas counter-attack-the best form of tumor defense?. Nature Med. 1999, 5:267-268.
231. Myers J.N., Yasamura S., Suminiami Y., Hirabayashi H., Lin W., Johnson J.T., Lotze M.T., Whiteside T.L. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin-4. Clin. Cancer Res. 1996, 2:127-135.
232. Byron K.A., Varigos G.A., Wootton A.M. IL-4 production is increased in cigarette smokers. Clin. Exp. Immunol. 1994, 95:333-336.
233. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993, 53:5613-5616.
234. Lai P., Rabinowich H., Crowley-Nowich P.A., Bell M.C., Mantovani G., Whiteside T.L. Alteration in expression and function of signal transducing proteins in tumor associated T and NK cells in patients with ovarian carcinoma. Clin. Cancer Res. 1996, 2:161-173.
235. Zea A.H., Curti B.D., Longo D.L., Alvord W.G., Strobl S.L., Mizoguchi H., Creekmore S.P., O'Shea J.J., Powers G.C., Urba W.J., Ochoa A.O. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1995, 1:1327-1335.
236. Matsuda M., Petersson M., Lenkei R., Taupin J.L., Magnusson I., Mellstedt H., Anderson P., Kiessling R. Alterations in the signal transducing molecules of T cells and NK cells in colorectal tumor infiltrating gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. Int. J. Cancer 1995, 61:765-772.
237. Rabinowich H., Reichert T.E., Kashii Y., Gastman B.R., Bell M.C., Whiteside T.L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. J. Clin. Invest. 1998, 101:2579-2588.
238. Mozoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transudction molecules in T lymphocytes from tumor-bearing mice. Science 1992, 258:1795-1798.
239. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J.L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal transducing zeta chains in tumor infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993, 53:5610-5612.
240. Reichert T.E., Rabinowich H., Johnson J.T., Whiteside T.L. Mechanisms responsible for signaling and functional defects. J. Immunother. 1998, 21:295-306.
241. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 1996, 2:1096-1103.
242. Young M.R.I., Schmidt-Pak A., Wright M.A., Matthews J.P., Collins S.L., Petruzzelli G. Mechanisms of immune suppression in patients with head and neck cancer: Presence of immune suppressive CD34+ cells in cancers that secrete granulocytemacrophage colony-stimulating factor. Clin. Cancer Res. 1995, 1:956-10361.
243. Eisma R.J., Spiro J.D., Kreutzer D.L. Role of angiogenic factors: Coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck carcinoma. Laryngoscope 1999, 109:687-693.
244. Hadden J.W. The immunopharmacology of head and neck cancer: An update. Int. J. Immunopharmacol. 1997, 19:629-644.
245. Lawlor G.J., Stiehm E.R., Kaplan M.S., Sengar D.P.S., Terasaki P.I. Phytohemagglutinin (PHA) skin test in the diagnosis of cellular immunodeficiency. J. Allergy Clin. Immunol. 1973, 52:31-37.
246. Hadden J.W. T-cell adjuvancy. Int. J. Immunopharmacol. 1994, 16:703-710.
247. Verastegui E., Barrera J.L., Zinser J., del Rio R., Meneses A., de La Garza J., Hadden J.W. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. Int. J. Immunopharmacol. 1997, 19:619-627.
248. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. 1996, 46:5-27.
249. Whiteside T.L. Tumor-infiltrating lymphocytes in head and neck cancer. Immunotherapy of Cancer With Sensitized T Lymphocytes 1994, 133-154. Landes Co., New York. A.E. Chang, S. Shu (Eds.).
250. Reichert T.E., Day R., Wagner E.M., Whiteside T.L. Absent or low expression of the ξ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998, 58:5344-5347.
251. Medina J.E. The controversial role of BCG in treatment of squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 1983, 109:543.
252. Vogl S.E., Schoenfeld D.A., Kaplan B.H., Lerner H.J., Horton J., Creech R.H. Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 1982, 50:2295-2300.
253. Vlock D.R., Johnson J., Myers E., Day R., Gooding W.E., Whiteside T.L., Pelch J., Sigler B., Wagner R., Colao D., et al. Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck 1991, 13:15-21.
254. Vlock D.R., Andersen J., Kalish L.A., Johnson J.T., Kirkwood J.M., Whiteside T.L., Herberman R.B., Adams G.S., Oken M.M., Haselow R.E. Phase II trial of interferon-alpha in locally-recurrent or metastatic squamous cell carcinoma of the head and neck: Immunological and clinical correlates. J. Immunother. 1996, 19:433-436.
255. Forni G., Giovarelli M., Jemma C., Bosco M.C., Caretto P., Modesti A., Forni M., Cortesina G., de Stefani A., et al. Perilymphatic injections of cytokines: A new tool in active cancer immunotherapy. Ann. Ist. Super Sanita 1990, 26:397-409.
256. Cortesina G., DeStefani A., Galeazzi E., Cavallo G.P., Jemma C., Giovarelli S., Forni G. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 1991, 13:125-131.
257. Cortesina G., DeStefani A., Galeazzi E., Cavallo G.P., Badellino F., Jemma C., Forni G. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin-2 injected perilymphatically. Br. J. Cancer 1994, 69:572-576.
258. DeStefani A., Valente G., Forni G., Lerda W., Ragona R., Cortesina G. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: Clinical and pathologic correlations. J. Immunother. Emphasis Tumor Immunol. 1996, 19:125-133.
259. Mattijssen V., DeMulder P.H., Schoznagel J.H., Verweij J., Galazka A., Roy S., Ruiter D.J. Clinical and immunopathologic results of a phase II study of perilymphatically injected interleukin-2 in locally far advanced non-pretreated head and neck squamous cell carcinoma. J. Immunother. 1991, 10:63-68.
260. Vlock D.R., Snyderman C., Johnson J.T., Myers E.N., Eibling D.E., Rubin J., Kirkwood J.M., Dutcher J.P., Adams G.L. Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial. J. Immunother. 1996, 19:433-442.
261. Whiteside T.L., Letessier E., Hirabayashi H., Vitolo D., Bryant J., Barnes L., Snyderman C., Johnson J.T., Myers E., Herberman R.B., et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993, 53:5654-5662.
262. Richtsmeier W.J., Koch W.M., McGuire W.P., Poole M.D., Chang E.H. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant interferon gamma. Arch. Otolaryngol. Head Neck Surg. 1990, 116:1271-1277.
263. Verastegui E., Barrera J.L., Zinser J., Zinser J., de la Garza J., Hadden J.W. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. Int. J. Immunopharmacol. 1997, 19:619-627.
264. Meneses A., Verastegui E., Barrera J.L., Zinser J., de la Garza J., Hadden J.W. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery. Arch. Pathol. Lab. Med. 1998, 122:447-454.
265. Barrera J.L., Verastegui E., Meneses A., Zinser J., de la Garza J., Hadden J.W. Combination immunotherapy of squamous cell carcinoma of the head and neck: A phase 2 trial. Arch. Otolaryngol. Head Neck Surg. 2000, 126:345-351.
266. Mantovani G., Gebbia V., Airoldi M., Bumma C., Contu P., Bianchi A., Dessi D., Massa E., Curreli L., Lampis B., Lai P., Mulas C., Testa A., Proto I., Cadeddu G., Tore G. Neoadjuvant chemo-(immuno-) therapy of advanced squamous-cell head and neck carcinoma: A multicenter, phase III, randomized study comparing cisplatin+5-fluorouracil (5-FU) with cisplatin+5-FU+recombinant interleukin 2. Cancer Immunol. Immunother. 1998, 47:149-156.
267. Evans T.R., Kaye S.B. Retinoids: Present role and future potential. Br. J. Cancer 1999, 80:1-8.
268. Wan H., Oridate N., Lotan D., Hong W.K., Lotan R. Overexpression of retinoic acid receptor beta in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Cancer Res. 1999, 59:3518-3526.
269. Van Zandwijk N., Dalesio O., Pastorino U., de Vries N., van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer: For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl. Cancer Inst. 2000, 92:977-986.
270. Nikolaou A.C., Fountzilas G., Daniilidis I. Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha: A phase II study. J. Laryngol. Otol. 1996, 110:857-861.
271. Milanovich M.R., Snyderman C.H., Wagner R., Johnson J.T. Prognostic significance of prostaglandin E2 production by mononuclear cells and tumor cells in squamous cell carcinomas of the head and neck. Laryngoscope 1995, 105:61-65.
272. Snyderman C.H., Milanovich M., Wagner R.L., Johnson J.T. Prognostic significance of prostaglandin E2 production in fresh tissues of head and neck cancer patients. Head Neck 1995, 17:108-113.
273. Hirsch B.E., Johnson J.T., Rabin B.S., Thearle P.B. Immunostimulation of patients with head and neck cancer: In vitro and preliminary clinical experiences. Arch. Otolaryngol. 1983, 109:298-301.
274. Cragg M.S., French R.R., Glennie M.J. Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 1999, 11:541-547.
275. De Bree R., Roos J.C., Quak J.J., den Hollander W., Snow G.B., van Dongen G.A. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin. Cancer Res. 1995, 1:591-598.
276. van Hal N.L., van Dongen G.A., Rood-Knippels E.M., Van Der Valk P., Snow G.B., Brankenhoff R.H. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int. J. Cancer 1996, 68:520-527.
277. van Gog F.B., Visser G.W., Stroomer J.W., Roos J.C., Snow G.B., van Dongen G.A. High dose rhenium-186-labeling of monoclonal antibodies for clinical applications: Pitfalls and solutions. Cancer 1997, 80:2360-2370.
278. de Bree R., Roos J.C., Plaizier M.A., Quak J.J., van Kamp G.J., Snow G.B., van Dongen G.A. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Br. J. Cancer 1997, 75:1049-1060.
279. van Gog F.B., Brakenhoff R.H., Stigter-van Walsum M., Snow G.B., van Dongen G.A. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int. J. Cancer 1998, 77:13-18.
280. Squadrelli-Saraceno M., Rivoltini L., Cantu G., Ravagnani F., Parminai G., Molinari R. Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 1991, 76:566-571.
281. Ikawa T., Eura M., Fukiage T., Murakami H., Yamasaki S., Fukuda K., Arishima S., Haehara T., Ishikawa T. Adoptive immunotherapy by intraarterial infusion of ATLAK or allo-TLAK cells in patients with head and neck cancer. Gan To Kagaku Ryoho 1989, 16:1438-1447.
282. Rosenberg S.A., Yanelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86:1159-1166.
283. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 1997, 3:2703-2707.
284. 264-272 peptide in cancer patients: Implication for immunoselection of epitope-loss variants. J. Immunol. 2000, 165:5938-5944.
285. Shichijo S., Nakao M., Imai Y., Takasu H., Kawamoto M., Niiya F., Yang D., Yamana H., Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med. 1998, 187:277-288.
286. Ito M., Schichijo S., Miyagi Y., Kobayashi T., Tsuda N., Yamada A., Saito N. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int. J. Cancer 2000, 88:633-639.
287. Kao H., Marto J.A., Hoffmann T.K. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells 2001, Submitted for publication.
288. Mandruzzato S., Brasseur F., Andry G., Boon T., van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 1997, 186:785-793.
289. Chikamatsu K., Nakano K., Storkus W.J., Appella E., Lotze M.T., Whiteside T.L., DeLeo A.B. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res. 1999, 5:1281-1288.
290. DeLeo A.B. p53-based immunotherapy of cancer. Crit. Rev. Immunol. 1998, 18:29-35.
291. Henry F., Boisteau O., Bretaudeau L., Lieubeau B., Meflah K., Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 1999, 59:3329-3332.
292. Hoffmann T.K., Meidenbauer N., Dworacki G., Kanaya H., Whiteside T.L. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000, 60:3542-3549.
293. De Zoeten E., Carr-Brendel V., Markovic D., Taylor-Papdimitriou J. Immunity to breast cancer in mice immunized with semi-allogeneic fibroblasts transfected with DNA from breast cancer cells. J. Immunol. 1999, 162:6934-6941.
294. Cohen E.P. Cancer therapy with DNA-based vaccines. Immunol. Lett. 2000, 74:59-65.
295. Nagashima S., Reichert T.E., Kashii Y., Suminami Y., Chikamatsu K., Whiteside T.L. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2. Cancer Gene Ther. 1997, 4:366-376.
296. Tzai T.S., Lin J.S., Chow N.H. Modulation of antitumor immunity of tumor-bearing mice with low dose cyclophos-phamide. J. Surg. Res. 1996, 65:139-144.
297. Gleich L.L. Gene therapy for head and neck cancer. Laryngoscope 2000, 110:708-726.
298. Tahara H., Elder E., Zitvogel L. Interleukin 12 (IL-12) gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts: A phase I clinical trial 2001, Submitted for publication.
299. Shu S., Chou T., Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J. Immunol. 1989, 143:740-748.
300. Whiteside T.L. Cellular adoptive immunotherapy: Expectations and reality. The Biotherapy of Cancers: From immunotherapy to Gene Therapy 1998, 239-262. Les Editions INSERM, Austin, TX. S. Chouaib (Ed.).
301. To W.C., Wood B.G., Krauss J.C., Strome M., Esclamado R.M., Lavertu P., Kim J.A., Plautz G.E., Leff B.E., Smith V., Sandstrom-Wakeling K., Shu S. Systemic adoptive T cell immunotherapy in recurrent and metastatic carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2000, 126:1225-1231.
302. Whiteside T.L., Reichert T.E., Dou P.Q. Interleukin-2 and its receptors in human solid tumors: Immunobiology and clinical significance. Cancer Metastasis Biol. Treat 2002, (in press).
303. Saito T., Kuss I., Dworacki G., Gooding W., Johnson J.T., Whiteside T.L. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin. Cancer Res. 1999, 5:1263-1273.
304. Harari P.M., Huang S. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:427-433.